Introduction to the bioequivalence theme issue.

Back in 2009, we concluded that veterinary pharmacology was sorely in need of a bioequivalence initiative. Despite the pharmacological and statistical advances that have occurred since the early days of bioequivalence assessments, unresolved issues remain. While many of these issues are common to both human and veterinary medicine, there are also challenges specific to veterinary drug products. To address this need, we constructed a four-pronged approach for facilitation of these complex issues: